“Next Year” for Embryonic Stem Cells?
by David Prentice
October 31, 2009
Geron now says that it hopes its embryonic stem cell experiment on spinal cord injury patients might begin in the 3rd quarter of 2010. The original FDA approval to test the cells in patients was given in January 2009 and Geron claimed it would begin in the summer of 2009, but before a single desperate patient had been injected with the potentially-dangerous cells, the FDA placed a hold on the Geron experiment due to safety concerns.
Meanwhile, the obsession with embryonic stem cells has obscured the real hope for patients–ADULT STEM CELLS. Peer-reviewed evidence of adult stem cell success for spinal cord injury patients has already been published by groups in Portugal, in Australia, in Ecuador, and in Brazil.
Of course, Geron’s latest announcement achieved its primary goal–Geron stock rose as much as 12%.
The Geron Prophecies
30 October 2009
Geron expects the data from this study to enable re-initiation of the clinical trial in the third quarter of 2010.
27 January 2009
Geron says that it expects to begin enrolment early this summer at up to seven US medical centres.
20 October 2008
A clinical trial that would test the use of embryonic stem cells to treat spinal cord injury could begin within three months.
17 October 2008
But the FDA is nearing the end of its review process and may lift the hold and allow clinical trials to commence within the next three months, Okarma told The Scientist.
15 May 2008 Continue reading »
The Geron Corporation announced Wednesday that its plans to begin the first clinical trial using embryonic stem cells had been delayed by federal regulators. While companies typically do not announce when they submit an application to begin a trial for an investigational new drug, the F.D.A.’s action means Geron must have submitted its application in the last 30 days, Mr. Benjamin said.



